Event time: 事件时间： 29/10/2026 10:45:00 UTC 2026/10/29 10:45:00 UTC
Published: 文章发布： 29/10/2026 16:43:07 UTC 2026/10/29 16:43:07 UTC
Key Results
Actual vs Consensus EPS: $7.48 vs $5.68 estimate, beat+31.7%. Revenue: $24.4B vs $22.6B estimate, beat+8.0%.
Profitability and Cash Flow Period: 2026 Q3 period ended 2026-09-30 Revenue: $24.4B; YoY: +38.6%; QoQ: +6.2% Gross profit: $16.3B; Gross margin: 66.7% Operating income: $8.9B; Operating margin: 36.5%; YoY: +6.3%; QoQ: -28.5% Net income: $6.5B; GAAP diluted EPS: $7.22; YoY: +15.6%; QoQ: -9.1% Operating cash flow: $11.4B; Capex: $3.2B; Free cash flow: $8.2B Cash: $4.9B; Total debt: $49.5B; Net debt: $44.6B
Official release: Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
核心结果
实际值与市场预期 EPS：$7.48 vs $5.68 预期，高于预期+31.7%。 营收：$24.4B vs $22.6B 预期，高于预期+8.0%。
财务指标 期间：2026 Q3（截至 2026-09-30） 营收：$24.4B；同比：+38.6%；环比：+6.2% 毛利润：$16.3B；毛利率：66.7% 经营利润：$8.9B；经营利润率：36.5%；同比：+6.3%；环比：-28.5% 净利润：$6.5B；GAAP 稀释 EPS：$7.22；同比：+15.6%；环比：-9.1% 经营现金流：$11.4B；资本开支：$3.2B；自由现金流：$8.2B 现金：$4.9B；总债务：$49.5B；净债务：$44.6B 
